All articles by GlobalData Healthcare

  1. J&J discontinues development for C. difficile antibiotic, Cadazolid

    In its earnings presentation this week, Johnson & Johnson (J&J) announced that it had ended its clinical development program for…
    Read More…

    20 Apr
  2. Marijuana: possible solution to the opioid crisis

    In 2016, more than 110 people died every day due to opioid overdose in the US. The opioid crisis has…
    Read More…

    20 Apr
  3. Sanofi’s next steps following NICE’s rejection of Dupixent

    In the first week of April, the National Institute for Health and Care Excellence (NICE) reject Sanofi’s Dupixent (dupilumab) for…
    Read More…

    20 Apr
  4. Can AI and blockchain tech help bring drug prices down?

    Prescription drug prices, particularly in the US, have been skyrocketing over the past decade at a significantly higher rate than…
    Read More…

    19 Apr
  5. FDA grants priority review for Verastem’s Duvelisib but toxicities weaken its prospects

    The FDA has accepted a new drug application (NDA) for Verastem’s duvelisib, and earlier this week granted it priority review….
    Read More…

    18 Apr
  6. AnaptysBio’s ANB-020 remains a strong potential contender in the peanut allergy market

    Early top-line results from AnaptysBio’s Phase IIa trial of its IL-33-inhibiting biologic, ANB-020, in adult peanut allergy patients were released…
    Read More…

    18 Apr
  7. Incyte’s clinical trial flop indicates an uncertain future for IDO inhibitors

    An update on the KEYNOTE-252/ECHO-301 trial for Incyte/Merck’s Phase III drug combo in metastatic melanoma, epacadostat + Keytruda, rocked the…
    Read More…

    18 Apr
  8. AstraZeneca deal shows promise for Molecular Partners’ lung cancer therapy

    A new epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treatment may be on the horizon for Molecular…
    Read More…

    17 Apr
  9. Azeliragon: The third Alzheimer’s failure of 2018

    After the termination of Takeda’s pioglitazone and Merck & Co.’s verubecestat, vTv Therapeutic’s azeliragon is now the third pipeline drug…
    Read More…

    17 Apr
  10. Biosimilar frontrunner Celltrion to lose first-to-market advantage for Truxima in the US

    Celltrion, the South Korean biopharma company responsible for the launch of Truxima, the first-ever Rituxan biosimilar for oncology, faced a…
    Read More…

    13 Apr